36th week of 2014 patent applcation highlights part 28 |
Patent application number | Title | Published |
20140248216 | DRUG DELIVERY BY CARBON NANOTUBE ARRAYS - The invention generally relates to carbon nanotube based drug delivery methods, devices, and compositions. More particularly, the invention relates to controlled drug delivery using anchored carbon nanotube arrays. | 2014-09-04 |
20140248217 | Methods of Identifying Xenohormetic Phenotypes and Agents - Methods of identifying a xenohormetic induced phenotype in an organism are provided. Also provided are methods if using organisms having a known xenohormetically induced phenotype in a number of different applications, such as the identification of xenohormetic agents and the generation of chemical entities and foodstuffs under specific conditions of production governed by xenohormetic effects. | 2014-09-04 |
20140248218 | ROS-SENSITIVE FLUORESCENT PROBES - Herein are provided, inter alia, compositions including boronic esters, which in the presence of H | 2014-09-04 |
20140248219 | SUBSTANTIALLY NON-AQUEOUS FOAMABLE PETROLATUM BASED PHARMACEUTICAL AND COSMETIC COMPOSITIONS AND THEIR USES - The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject in need thereof, comprising administering the above-mentioned compositions to an afflicted target site of said mammalian subject. | 2014-09-04 |
20140248220 | FOAMABLE SUSPENSION GEL - The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent. | 2014-09-04 |
20140248221 | COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS - Compositions containing polymetal complexes useful in treating disorders of the oral mucosa, lips, and perioral regions are described. | 2014-09-04 |
20140248222 | DENTAL VARNISH COMPOSITIONS - Disclosed herein are substantially transparent and colorless dental varnishes having improved fluoride release, transparency and color once coated. | 2014-09-04 |
20140248223 | FILM COMPOSITIONS FOR DELIVERY OF ACTIVES - The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain at least one active agent, which may be administered to a user topically, transmucosally, vaginally, ocularly, aurally, nasally, transdermally or orally. | 2014-09-04 |
20140248224 | AQUEOUS PHOTO-PROTECTIVE PERSONAL CARE COMPOSITION - The invention relates to a high SPF/UVAPF sunscreen composition. It is an object of the present invention to provide an SPF of at least 10 and a UVAPF of at least 2. This is achieved by inclusion of a select emollient in a sunscreen containing composition comprising a cosmetically acceptable base comprising volatile silicone and silicone elastomer. | 2014-09-04 |
20140248225 | NAIL-HARDENING COSMETIC COMPOSITION, USE OF ALDEHYDES TO HARDEN AND STRENGTHEN NAILS, AND METHOD FOR APPLYING SAME - A cosmetic composition for nails containing a concentration less than or equal to 1 wt % of at least one monoaldehyde of the formula (I): R—CHO, where R is C5-C12 linear alkyl radical or a C5-C12 alkenyl with an unconjugated double bond to the —CHO aldehyde group, as nail hardening agent, and provided in the form of a colored or colorless fingernail polish, a polish undercoat, a peelable polish, a beauty oil, an emulsion or an aqueous solution, or a gel. Also the use of aldehydes of the formula (I) for hardening and strengthening nails and to a method for applying same. | 2014-09-04 |
20140248227 | DEODORIZING COMPOSITIONS - Cosmetic compositions for reducing body odor include a) at least one alkoxybenzene compound having the structural formula (I), having the residues R | 2014-09-04 |
20140248228 | HAIR TREATMENT COMPOSITION WITH CATIONIC CARE SUBSTANCE AND UV FILTER - Hair treatment agents combining improved care effects, in particular improved combability, softness and shine of the hair, with a viscosity stability over wide temperature ranges include—relative to their weight—0.1 to 20 wt. % of at least one UV filter and 0.1 to 30 wt. % of at least one compound of the general formula (I), in which n and m independently of one another denote integers between 5 and 40, with the proviso that n+m≧38; a and b independently of one another denote integers between 1 and 10; R and R′ are selected independently of one another from —H and —CH | 2014-09-04 |
20140248229 | NOURISHING HAIR TREATMENT COMPOSITION - Hair treatment compositions, including at least one quaternary imidazoline derivative having at least two long fat residues of the formula (I) set forth herein, in which the R | 2014-09-04 |
20140248230 | HAIR CARE TREATMENT AGENT - Hair treatment agents include at least one quaternary ammonium compound according to formula (I), in which n denotes an integer from 10 to 24 and X | 2014-09-04 |
20140248231 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT - Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch. | 2014-09-04 |
20140248232 | BIODEGRADABLE, NON-THROMBOGENIC ELASTOMERIC POLYURETHANES - A method of forming an implantable article includes providing a biodegradable polymer including anti-thrombogenic groups along the length of the biodegradable polymer, biodegradable groups in the backbone of the biodegradable polymer and a plurality of functional groups adapted to react with reactive functional groups on a surface of the implantable article, and reacting at least a portion of the plurality of functional groups with the reactive functional groups on the surface of the implantable article. | 2014-09-04 |
20140248233 | BIOCOMPATIBLE COMPOSITE MATERIALS - An injectable composite material comprising a fibrous material comprised of a fir biocompatible low melting point polyester dispersed in a host medium comprised of second biocompatible low melting point polyester. | 2014-09-04 |
20140248234 | USE OF G-CSF DIMER IN PREPARATION OF MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function of dopaminergic neurons. In addition, the G-CSF dimer can significantly reduce apoptosis of neuron in hippocampus and improve learning and memory ability of AD model rats. Serum half-life of the G-CSF dimer of the invention is prolonged and the loss of neurons is effectively prevented, providing a better therapeutic effect in treatment of neurodegenerative disease. | 2014-09-04 |
20140248235 | Methods of Use for IL-22 Promoting Rejuvenation Of Thymic And Bone Marrow Function - The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination. | 2014-09-04 |
20140248236 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION - The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes. | 2014-09-04 |
20140248237 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 2014-09-04 |
20140248238 | POLYPEPTIDE CONSTRUCTS AND USES THEREOF - The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen. | 2014-09-04 |
20140248239 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS - Compounds of formula I | 2014-09-04 |
20140248240 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) - The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: Formula (I) | 2014-09-04 |
20140248241 | 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-deoxy nucleoside compounds according to Formula 3001a or 3001b: | 2014-09-04 |
20140248242 | THIOPHOSPHATE NUCLEOSIDES FOR THE TREATMENT OF HCV - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: | 2014-09-04 |
20140248243 | VIRUS-LIKE PARTICLES FOR TREATMENT OF VIRAL INFECTIONS - The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus. | 2014-09-04 |
20140248244 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors - Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 | 2014-09-04 |
20140248245 | DIAGNOSTIC METHOD FOR CONNECTIVE TISSUE AND ITS APPLICATION - The present invention relates to medicine and is used to evaluate conditions and to detect connective tissue pathology (and/or organ) by clonal analysis. The present invention relates to aesthetic medicine and is used for correction of aging skin changes. The method includes: cultivation of substrate-dependent cell colonies of analyzed tissue and/or organ, at conditions which provide formation of discrete colonies applicable for visualization, statistically reliable analysis of derived colonies, determination of at least one parameter which characterizes regenerative potential of population of substrate dependent cells, determination of at least one parameter which characterizes proliferative potential of population of substrate dependent cells, and processing of obtained results which allows to evaluate regenerative ability of patient's tissue and/or organ. The method provides objective qualitative characteristics of both the proliferative and regenerative potential which allows evaluating the regenerative potential of primary tissue (and/or organ) without complex and expensive instrumental studies. A computer based system for performing the present method is also provided. | 2014-09-04 |
20140248246 | EDIBLE WEB COMPRISING MICROORGANISMS - The present invention relates to edible webs comprising microorganisms, such as probiotics. In particular, the present invention relates to an edible web having microorganisms, such as bacteria, probiotic bacteria, bacteriophages or viruses printed thereon, e.g. by the use of inkjet printing. In addition the invention relates to methods of producing such edible webs, to various products comprising the edible webs as well as to use of the edible webs comprising microorganisms. | 2014-09-04 |
20140248247 | COMPOSITION FOR USE IN THE PROMOTION OF HEALTHY BONE GROWTH AND/OR IN THE PREVENTION AND/OR TREATMENT OF BONE DISEASE - The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease. Said bone disease is in particular osteomalacia, rickets, osteopenia or osteoporosis. Preferably the composition is a nutritional composition. | 2014-09-04 |
20140248248 | HUMAN PROGENITOR T-CELLS - Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy. | 2014-09-04 |
20140248249 | METHOD FOR STABILIZATION AND DELIVERY OF THERAPEUTIC MOLECULES - A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and one or more of a natural molecule or fragment thereof in at least one carrier to a patient in need of treatment, wherein the natural molecule is non-acetylated, non-Esterified, and non-fatty acid attached. | 2014-09-04 |
20140248250 | AGENT EXHIBITING BACTERICIDAL ACTION WITH RESPECT TO VEGETATIVE AND SPORE CELLS BACILLUS ANTHRACIS, ANTHRAX PREVENTING AND TREATING METHOD - The drug has a bactericidal effect on vegetative and spore cells of | 2014-09-04 |
20140248251 | Methods and Pharmaceutical Compositions for Treating Celiac Disease and Gluten Intolerance - The invention concerns methods for protecting a subject in need from a deleterious effect of gluten ingestion. The invention specifically concerns the treatment of celiac disease and gluten intolerance. The invention further provides pharmaceutical compositions for protecting a subject in need from a deleterious effect of gluten ingestion, and, in particular, for treating celiac disease and gluten intolerance. Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten-intolerance from the harmful effects of ingesting food containing gluten. | 2014-09-04 |
20140248252 | New Salt And Medical Use - The present invention is directed to 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof for the treatment of a disease associated with elevated blood uric acid levels, such as hyperuricemia or gout. The invention is also directed to the tosylate salt of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide. | 2014-09-04 |
20140248253 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CNS INJURIES - The present invention is directed to a method of improving functional recovery following a central nervous system contusion injury. The method includes administering a therapeutically effective amount of glycosaminoglycan degrading enzyme. The glycosaminoglycan degrading enzyme may be dermatan sulfate or chondroitin sulfate degrading enzymes. The central nervous system contusion injury may include a traumatic brain injury or a spinal cord injury. The functional recovery may include autonomic functions, sensory functions, motor functions or the like. | 2014-09-04 |
20140248254 | THE USE OF ACHE AS NUCLEASE - This invention provides the use of AChE as nuclease. The use of AChE in regulating the stability of nucleic acid and cell apoptosis, as well as a series of agents based on the use, including the agents for promoting or inhibiting cell apoptosis, the agents for inhibiting tumors, and the agents for protecting nucleic acid from impairing, are provided. | 2014-09-04 |
20140248255 | Novel Asparaginase and Treating Diseases Associated With Asparagine Dependence - Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to | 2014-09-04 |
20140248256 | DIMERIC BACTERIOPHAGE LYSINS - The present invention provides isolated dimeric | 2014-09-04 |
20140248257 | COMBINATION THERAPY FOR ISCHEMIA - The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment invoices administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g. by administration of tPA). Administration a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered. | 2014-09-04 |
20140248258 | METHODS FOR IMPROVING GUT HEALTH - The present invention provides methods for improving gut health. In particular, the invention provides methods for improving gut health by improving the digestibility of dietary proteins, decreasing the flow of protein to the lower gastrointestinal tract, and/or decreasing the levels of | 2014-09-04 |
20140248259 | Compositions and Methods for Modulating Hemostasis - Factor X/Xa variants and methods of use thereof are disclosed. | 2014-09-04 |
20140248260 | USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER - The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist. | 2014-09-04 |
20140248261 | ANTIBODY AGAINST MUTANT ALPHA-ACTININ-4 - An antibody against mutant α-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of α-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region. | 2014-09-04 |
20140248262 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer. | 2014-09-04 |
20140248263 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE - Compounds having a structure of Formula I: wherein G, a, Q, L | 2014-09-04 |
20140248264 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY - Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof. | 2014-09-04 |
20140248265 | THERAPEUTIC ANTIBODIES BINDING IL 12RBETA1 - The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNy production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNy production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders. | 2014-09-04 |
20140248266 | ANTI-CD40 ANTIBODY MUTANTS - A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2. | 2014-09-04 |
20140248267 | ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME - The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies. | 2014-09-04 |
20140248268 | Rab7 GTPase Inhibitors and Related Methods of Treatment - This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided. | 2014-09-04 |
20140248269 | MEDICINAL AGENT FOR PREVENTING EXACERBATION OF MALIGNANT TUMOR, COMPRISING COMBINATION OF NATRIURETIC PEPTIDE RECEPTOR GC-A AND GC-B AGONISTS - Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind of natriuretic peptide receptor GC-A agonist and at least one kind of natriuretic peptide receptor GC-B agonist to be administered in combination; a therapeutic method comprising administering the agent; etc. | 2014-09-04 |
20140248270 | METHOD FOR TOPICAL TREATMENT OF TAR-RESPONSIVE DERMATOLOGICAL DISORDERS - A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the composition being in liquid form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal. | 2014-09-04 |
20140248271 | NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY - This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein. | 2014-09-04 |
20140248272 | RECOMBINANT PROTEINS FOR USE IN VACCINE, ANTIBODIES AGAINST SAID PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC METHODS INCLUDING THE SAME - The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in | 2014-09-04 |
20140248273 | VACCINE BASED ON STAPHYLOCOCCAL SUPERANTIGEN-LIKE 3 PROTEIN (SSL3) - The present invention relates to the field of vaccinology, especially of vaccines against | 2014-09-04 |
20140248274 | STABLE LYOPHILIZED PHARMACEUTICAL PREPARATIONS OF MONOCLONAL OR POLYCLONAL ANTIBODIES - The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilisate as well as the use of a sugar or amino sugar, an amino acid and a surfactant as stabilizers for therapeutic or diagnostic agents containing antibodies. | 2014-09-04 |
20140248275 | MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS - Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. | 2014-09-04 |
20140248276 | MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS - Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. | 2014-09-04 |
20140248277 | MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS - Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. | 2014-09-04 |
20140248278 | ANTI-CD22 ANTIGEN BINDING MOLECULES TO TREAT LUNG CANCER AND PROSTATE CANCER - This invention provides methods for preventing, reducing, delaying or inhibiting the proliferation and/or growth and/or metastasis of lung cancers and prostate cancer that express or overexpress CD22 by contacting the lung cancer cell or prostate cancer cell with an antigen binding molecule that binds to CD22 expressed on the surface of the cancer cell. | 2014-09-04 |
20140248279 | USE OF IL-23 AND IL-17 ANTIAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE - Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity. | 2014-09-04 |
20140248280 | ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH PACLITAXEL FOR TREATMENT OF GYNECOLOGICAL CANCERS - Provided are methods and compositions for clinical treatment of advanced gynecological cancers using anti-ErbB3 antibodies combined with paclitaxel. | 2014-09-04 |
20140248281 | ERYTHROPOIETIC ROLE OF RESIDENT MACROPHAGES IN HEMATOPOIETIC ORGANS - Methods of determining the erythroid prognosis of an anemia, methods of treating a blood disorder in a subject comprising an anemia, and methods of treating a blood disorder in a subject comprising an expanded erythron are all provided. | 2014-09-04 |
20140248282 | NOVEL ANTI-DDR1 ANTIBODY HAVING ANTI-TUMOR ACTIVITY - As a result of producing anti-DDR1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human DDR1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains. It was also found that the antibodies have one or more activities selected from the group consisting of: (i) an activity to suppress cell proliferation, (ii) an activity to inhibit cell migration, (iii) an activity to inhibit phosphorylation of DDR1 in cells, (iv) an activity to be taken up into cells, (v) an activity to decrease the expression level of DDR1 in cells, and (vi) an activity to decrease the expression level of TGF-β in cells. | 2014-09-04 |
20140248283 | MONOCLONAL ANTIBODIES AGAINST HER2 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express HER2 antigens. | 2014-09-04 |
20140248284 | METHODS FOR THE DETECTION AND THE TREATMENT OF CARDIAC REMODELING - The present invention relates to methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure. The present invention also relates to methods and pharmaceutical compositions for the prevention and the treatment of cardiac remodeling. | 2014-09-04 |
20140248285 | METHOD FOR PROTECTING PARVOVIRUS ANTIGEN - An improved method for the detection of parvovirus B19 in a sample is provided, the improvement consisting of detecting a parvovirus B19 non-structural protein in said sample. | 2014-09-04 |
20140248286 | ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE - The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. | 2014-09-04 |
20140248287 | FC RECEPTOR BINDING PROTEINS - This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders. | 2014-09-04 |
20140248288 | BIODEGRADABLE METAL ALLOYS - The invention relates to biodegradable, metal alloy-containing compositions, methods for their preparation and applications for their use. The compositions include magnesium and other components, such as yttrium, calcium, silver, cerium, and zirconium; or zinc, silver, cerium, and zirconium; or aluminum, zinc, calcium, manganese, silver, yttrium; or strontium, calcium, zinc. The compositions are prepared by vacuum induction/crucible melting together the components and casting the melted mixture in a preheated mild steel/copper mold. In certain embodiments, the compositions of the invention are particularly useful for forming medical devices for implantation into a body of a patient. | 2014-09-04 |
20140248289 | Methods and Compositions for the Treatment of Respiratory Conditions Via NKG2D Inhibition - Methods and compositions for the treatment of respiratory conditions are provided. Aspects of the subject methods include administering to the subject a composition comprising an inhibitor of NKG2D-mediated activation of leukocytes. Also provided are compositions suitable for use in the subject methods, as well as pharmaceutical preparations thereof. | 2014-09-04 |
20140248290 | INHIBITION OF CANCER METASTASIS - P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis. | 2014-09-04 |
20140248291 | Modulation of Cellular Migration - Methods, kits, and compositions are provided for addressing cancer through the interaction of bradykinin (BK) and the bradykinin-2-receptor (B2R). This interaction controls cellular invasion, as has been unexpectedly observed in glioma cells, A composition is provided for the treatment of cancer by disrupting this interaction using an inhibitor or BK or B2R that can. be administered to the subject. Diagnostic processes are provided, involving measuring levels of BK or B2R to determine the potential for cancer (or to determine the invasive potential of a given cancer). Modulators of BK. and B2R may be used to modulate cellular migration, both in vivo and in vitro. Potential modulators of cellular migration can be screened by measuring the effect of the potential modulator on BK or B2R, | 2014-09-04 |
20140248292 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention relates to compositions and methods for treating cancer. In particular, the present invention relates to EpCAM-targeted immunotoxins and uses thereof in treating peritoneal cancers expressing EpCAM (e.g., colorectal, ovarian, and pancreatic cancer). | 2014-09-04 |
20140248293 | NOVEL RISK BIOMARKERS FOR LUNG CANCER - Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of N-methylpurine DNA glycosylase (MPG), or apurinic/apyrimidinic endonuclease 1 (APE1), or both, or MPG and 8-oxoguanine DNA glycosylase (OGG1), or MPG and APE1 and OGG1 in peripheral blood cells of a subject, wherein levels of MPG above a predetermined reference value, or APE1 or OGG1, or a integrated DNA repair score below a predetermined reference value is indicative of an increased risk of developing lung cancer. | 2014-09-04 |
20140248294 | WNT4 AND MED12 FOR USE IN THE DIAGNOSIS AND TREATMENT OF TUMOR DISEASES - Provided are novel methods and compositions for the diagnosis, prognosis and treatment of gynecological tumors, in particular uterine leiomyoma (UL). Furthermore, novel methods and compositions for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of pituitary and prostate tumors are described. | 2014-09-04 |
20140248295 | GLYCAN-MODIFIED ANTI-CD4 ANTIBODIES FOR HIV PREVENTION AND THERAPY - Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed. | 2014-09-04 |
20140248296 | SUSTAINED DRUG DELIVERY SYSTEM - A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. | 2014-09-04 |
20140248297 | PREDICTORS OF RESPONSE TO IMMUNOTHERAPY - The invention is directed to a method to predict individuals who are likely to respond to immunotherapy by detecting enhanced levels of antibodies in the plasma or serum wherein the antibodies are characteristic of the response or non-response of pretested populations of subjects. | 2014-09-04 |
20140248298 | BIORESORABLE POLYMER MATRICES AND METHODS OF MAKING AND USING THE SAME - Bioactive agents are delivered to a body site in need of the same by providing a first aliquot portion of a reaction mixture which includes an aldehydic polymer solution, and a second aliquot portion of a reaction which includes a cross-linking hydrazide and a bioactive agent. The first and second aliquot portions may be mixed (e.g., by expelling such portions from respective syringe barrels) to form the reaction mixture thereof. The thus formed reaction mixture may then be installed at the body site whereby the reaction mixture is allowed to solidify in situ within about 1 to 10 minutes into a reaction product comprised of a hydrazide cross-linked oxidized aldehydic polymer matrix with the bioactive agent entrapped therein. | 2014-09-04 |
20140248299 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (Ia): | 2014-09-04 |
20140248300 | PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS - The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines. | 2014-09-04 |
20140248301 | METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES - The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method. | 2014-09-04 |
20140248302 | RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES - A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats. | 2014-09-04 |
20140248303 | SYNTHETIC STREPTOCOCCUS PNEUMONIAE VACCINE - Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R2 | 2014-09-04 |
20140248304 | NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF UTILIZING SAME - The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest. | 2014-09-04 |
20140248305 | ADENOVIRAL VECTORS COMPRISING PARTIAL DELETIONS OF E3 - This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted. | 2014-09-04 |
20140248306 | LENTIVIRAL GENE TRANSFER VECTORS AND THEIR MEDICINAL APPLICATIONS - The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo. | 2014-09-04 |
20140248307 | AFFENADENOVIRUS (GORILLA) OR ADENOVIRAL VECTORS AND METHODS OF USE - The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein. | 2014-09-04 |
20140248308 | AFFENADENOVIRUS (GORILLA) OR ADENOVIRAL VECTORS AND METHODS OF USE - The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein. | 2014-09-04 |
20140248309 | DNA PROMOTERS AND ANTHRAX VACCINES - The invention is related to intracellularly induced bacterial DNA promoters and vaccines against | 2014-09-04 |
20140248310 | CATIONIC METAL OXIDES FOR USE AS VACCINE ADJUVANTS - Adjuvant and immunological vaccine compositions comprising modified, cationic metal oxides are disclosed, including methods of making modified, cationic metal oxides and methods of using the modified metal oxides in vaccine formulations and regimens. | 2014-09-04 |
20140248311 | N-TERMINAL DELETED GP120 IMMUNOGENS - The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same. | 2014-09-04 |
20140248312 | INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS - Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen; (ii) an insoluble particulate adjuvant; and (iii) a immunopotentiator. | 2014-09-04 |
20140248313 | COMBINATION ADJUVANT FORMULATION - Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen. | 2014-09-04 |
20140248314 | PRE-FUSION RSV F ANTIGENS - The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F. | 2014-09-04 |
20140248315 | METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE, BLOCKING MONOCYTE MIGRATION, AMPLIFYING VACCINE IMMUNITY AND INHIBITING TUMOR GROWTH AND METASTASIS - Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided. | 2014-09-04 |
20140248316 | HYBRID CELLS FOR TREATING CANCER PATIENTS - The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation. | 2014-09-04 |